ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease

Neoplasia

Volumn 8, Issue 4, 2006, Pages 319-329

  Kuefer, Rainer ^a,b   Day, Kathleen C ^a   Kleer, Celina G ^a   Sabel, Michael S ^a   Hofer, Matthias D ^b,c   Varambally, Sooryanarayana ^a   Zorn, Christoph S ^a   Chinnaiyan, Arul M ^a   Rubin, Mark A ^c   Day, Mark L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ULM   (Germany)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ADAM15 disintegrin; Breast cancer; cDNA microarray; Prostate cancer; Tissue microarray

Indexed keywords

COMPLEMENTARY DNA; DISINTEGRIN; GELATINASE A; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; PROTEIN ADAM15; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; GENE OVEREXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPECTROSCOPY; TISSUE MICROARRAY; UPREGULATION;

EID: 33646408392     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05682     Document Type: Article

References (59)

1. Bogenrieder T and Herlyn M (2003). Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22 (42), 6524-6536.
2. Polette M, Nawrocki-Raby B, Gilles C, Clavel C, and Birembaut P (2004). Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 49 (3), 179-186.
3. Wheelock MJ, Buck CA, Bechtol KB, and Damsky CH (1987). Soluble 80-kD fragment of cell-CAM 120/80 disrupts cell-cell adhesion. J Cell Biochem 34 (3), 187-202.
4. White JM (2003). ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol 15 (5), 598-606.
5. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, and Fitzner JN, et al. (1998). An essential role for ectodomain shedding in mammalian development. Science 282 (5392), 1281-1284.
6. Primakoff P and Myles DG (2000). The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet 16 (2), 83-87.
7. McCulloch DR, Harvey M, and Herington AC (2000). The expression of the ADAMs proteases in prostate cancer cell lines and their regulation by dihydrotestosterone. Mol Cell Endocrinol 167 (1-2), 11-21.
8. Wu E, Croucher PI, and McKie N (1997). Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem Biophys Res Commun 235 (2), 437-442.
9. Iba K, Albrechtsen R, Gilpin BJ, Loechel F, and Wewer UM (1999). Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am J Pathol 154 (5), 1489-1501.
10. Roy R, Wewer UM, Zurakowski D, Pories SE, and Moses MA (2004). ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 279 (49), 51323-51330.
11. Fischer OM, Hart S, Gschwind A, and Ullrich A (2003). EGFR signal transactivation in cancer cells. Biochem Soc Trans 31 (Part 6), 1203-1208.
12. Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, Tanke HJ, Schroder FH, and van Dekken H (2000). Identification of genetic markers for prostatic cancer progression. Lab Invest 80 (6), 931-942.
13. Glinsky GV, Krones-Herzig A, and Glinskii AB (2003). Malignancy- associated regions of transcriptional activation: gene expression profiling identifies common chromosomal regions of a recurrent transcriptional activation in human prostate, breast, ovarian, and colon cancers. Neoplasia 5 (3), 218-228.
14. Goeze A, Schluns K, Wolf G, Thasler Z, Petersen S, and Petersen I (2002). Chromosomal imbalances of primary and metastatic lung adenocarcinomas. J Pathol 196 (1), 8-16.
15. Qin LX (2002). Chromosomal aberrations related to metastasis of human solid tumors. World J Gastroenterol 8 (5), 769-776.
16. Nilsson M, Meza-Zepeda LA, Mertens F, Forus A, Myklebost O, and Mandahl N (2004). Amplification of chromosome 1 sequences in lipomatous tumors and other sarcomas. Int J Cancer, 109 (3), 363-369.
17. Martin J, Eynstone LV, Davies M, Williams JD, and Steadman R (2002). The role of ADAM 15 in glomerular mesangial cell migration. J Biol Chem 277 (37), 33683-33689.
18. Fourie AM, Coles F, Moreno V, and Karlsson L (2003). Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J Biol Chem 278 (33), 30469-30477.
19. Bohm BB, Aigner T, Roy B, Brodie TA, Blobel CP, and Burkhardt H (2005). Homeostatic effects of the metalloproteinase disintegrin ADAM15 in degenerative cartilage remodeling. Arthritis Rheum 52 (4), 1100-1109.
20. Al-Fakhri N, Wilhelm J, Hahn M, Heidt M, Hehrlein FW, Endisch AM, Hupp T, Cherian SM, Bobryshev YV, Lord RS, and Katz N (2003). Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and alphavbeta3 in atherosclerosis. J Cell Biochem 89 (4), 808-823.
21. Schafer B, Gschwind A, and Ullrich A (2004). Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 23 (4), 991-999.
22. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, and Pienta KJ (2000). Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 6 (3), 1038-1045.
23. Greene FL (2002). AJCC cancer staging manual of the American Joint Committee on Cancer and American Cancer Society. AJCC Cancer Staging Manual, 6th ed, Springer-Verlag, New York. p. 421.
24. Gleason D (1966). Classification of prostate carcinoma. Cancer Chemother Rep 50 (3), 125-128.
25. Gleason D and The Veterans Administration Cooperative Urological Research Group (1977). Histologic grading and clinical staging of prostate carcinoma. In M Tannenbaum, (Ed.), Urologic Pathology: The Prostate Lea and Febiger, Philadelphia. pp. 171-198.
26. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, and Kallioniemi OP (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4 (7), 844-847.
27. Perrone EE, Theoharis C, Mucci NR, Hayasaka S, Taylor JM, Cooney KA, and Rubin MA (2000). Tissue microarray assessment of prostate cancer tumor proliferation in African-American and white men. J Natl Cancer Inst 92 (11), 937-939.
28. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, and Chinnaiyan AM (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412 (6849), 822-826.
29. Rubin MA, Dunn R, Strawderman M, and Pienta KJ (2002). Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26 (3), 312-319.
30. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, and Chinnaiyan AM (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 10 (419(6907)), 624-629.
31. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, and Chinnaiyan AM (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6 (1), 1-6.
32. Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE, Maquoi E, Cataldo D, and Foidart JM (2004). Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol 57 (6), 577-584.
33. Handsley MM and Edwards DR (2005). Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 115 (6), 849-860.
34. Wolfsberg TG, Primakoff P, Myles DG, and White JM (1995). ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol 131 (2), 275-278.
35. Beck V, Herold H, Benge A, Luber B, Hutzler P, Tschesche H, Kessler H, Schmitt M, Geppert HG, and Reuning U (2005). ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion. Int J Biochem Cell Biol 37 (3), 590-603.
36. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, and Rocken C (2005). The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 26 (1), 17-24.
37. Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, and Rocken C (2005). Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 131 (1), 41-48.
38. Ortiz RM, Karkkainen I, and Huovila AP. (2004). Aberrant alternative exon use and increased copy number of human metalloprotease-disintegrin ADAM15 gene in breast cancer cells. Genes Chromosomes Cancer 41 (4), 366-378.
39. Schutz A, Hartig W, Wobus M, Grosche J, Wittekind Ch, and Aust G (2005). Expression of ADAM15 in lung carcinomas. Virchows Arch 446 (4), 421-429.
40. Hart S, Fischer OM, Prenzel N, Zwick-Wallasch E, Schneider M, Hennighausen L, and Ullrich A (2005). GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol Chem 386 (9), 845-855.
41. Rashid MG, Sanda MG, Vallorosi CJ, Rios-Doria J, Rubin MA, and Day ML (2001). Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. Cancer Res 61 (2), 489-492.
42. Rios-Doria J, Day KC, Kuefer R, Rashid MG, Chinnaiyan AM, Rubin MA, and Day ML (2003). The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem 278 (2), 1372-1379.
43. Rios-Doria J, Kuefer R, Ethier SP, and Day ML (2004). Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. Cancer Res 64 (20), 7237-7240.
44. Rios-Doria J and Day ML (2005). Truncated E-cadherin potentiates cell death in prostate epithelial cells. Prostate 63 (3), 259-268.
45. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, and Isaacs WB (2001). Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61 (12), 4683-4688.
46. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, and Milbrandt J (2001). Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61 (15), 5692-5696.
47. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, and Scardino PT (1998). A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (10), 766-771.
48. Kattan MW, Potters L, Blasko JC, Beyer DC, Fearn P, Cavanagh W, Leibel S, and Scardino PT (2001). Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 58 (3), 393-399.
49. Martin SA, Perez-Reyes N, and Mendelsohn G (1987). Angioinvasion in breast carcinoma. An immunohistochemical study of factor VIII-related antigen. Cancer 59 (11), 1918-1922.
50. Sinn HP, Anton HW, Magener A, von Fournier D, Bastert G, and Otto HF (1998). Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy. Eur J Cancer 34 (5), 646-653.
51. Watermann D, Madjar H, Sauerbrei W, Hirt V, Prompeler H, Stickeler E (2004). Assessment of breast cancer vascularisation by Doppler ultrasound as a prognostic factor of survival. Oncol Rep 11 (4), 905-910.
52. Horiuchi K, Weskamp G, Lum L, Hammes HP, Cai H, Brodie TA, Ludwig T, Chiusaroli R, Baron R, Preissner KT, Manova K, and Blobel CP (2003). Potential role for ADAM15 in pathological neovascularization in mice. Mol Cell Biol 23 (16), 5614-5624.
53. Nath D, Slocombe PM, Stephens PE, Warn A, Hutchinson GR, Yamada KM, Docherty AJ, and Murphy G (1999). Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. J Cell Sci 112 (Part 4), 579-587.
54. Eliceiri BP and Cheresh DA (1999). The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 103 (9), 1227-1230.
55. Fassler R and Meyer M (1995). Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev 9 (15), 1896-1908.
56. Kim S, Bell K, Mousa SA, and Varner JA (2000). Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156 (4), 1345-1362.
57. Seals DF and Courtneidge SA (2003). The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17 (1), 7-30.
58. Amour A, Knight CG, Webster A, Slocombe PM, Stephens PE, Knauper V, Docherty AJ, and Murphy G (2000). The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 473 (3), 275-279.
59. Loechel F, Fox JW, Murphy G, Albrechtsen R, and Wewer UM (2000). ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 278 (3), 511-515.